Protocol Ledger

NCT05919680 · Phase II · RECRUITING

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Interventional Phase II clinical trial protocol NCT05919680 sponsored by NorthSea Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-15 Enrollment: 36 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05919680
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05919680
Protocol FieldVerified Registry Value
NCT IdentifierNCT05919680
Consolidated Lead SponsorNorthSea Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment36 participants (ESTIMATED)
Registered Start Date2024-01-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI